Associations of Chinese Herbal Medicine Use with the Risks of Acute Exacerbation and Mortality in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
Restricted accessResearch articleFirst published online January, 2022
Associations of Chinese Herbal Medicine Use with the Risks of Acute Exacerbation and Mortality in Patients with Chronic Obstructive Pulmonary Disease: A Nationwide Retrospective Cohort Study
This study aimed to assess the correlation of exacerbation and the mortality rate in patients with chronic obstructive pulmonary disease (COPD) between biomedical treatments with or without Chinese herbal medicine (CHM) as an adjunct.
Design:
A total of 81,261 COPD patients were identified from the National Health Insurance Research Database in Taiwan between 2001 and 2012. After screening and matching, 3176 COPD patients were included in the study. Statistical analyses were performed to assess the differences in the baseline characteristics. The authors used the Cox proportional hazard regression analysis to calculate the risks of mortality and hospitalization due to acute exacerbation of COPD within 1 year between a CHM user cohort and non-CHM user cohort. The cumulative incidence of mortality in COPD patients with or without CHM treatment was calculated by the Kaplan–Meier method.
Results:
COPD patients in the CHM user cohort demonstrated a significantly lower risk of mortality (p < 0.001) and acute exacerbation (p < 0.05), compared with the non-CHM user cohort. In addition, the CHM users exhibited a reduced cumulative incidence of mortality compared with the non-CHM user cohort (p < 0.001). Xiao Qing Long Tang and Fritillariae thunbergii were the most common Chinese herbal formula and single Chinese herb prescribed for COPD patients.
Conclusion:
Combining CHM with biomedical treatment might reduce the risk of acute exacerbation and incidence of mortality in patients with COPD.
Get full access to this article
View all access options for this article.
References
1.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2020 Report), Global Initiative for Chronic Obstructive Lung Disease;2020.
2.
American Lung Association. Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality. American Lung Association Epidemiology and Statistics Unit Research and Health Education Division March 2013.
3.
LozanoR, NaghaviM, ForemanK, et al.Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet (London, England), 2012; 380:2095–2128.
4.
WedzichaJA, SeemungalTA. COPD exacerbations: Defining their cause and prevention. Lancet (London, England), 2007; 370:786–796.
5.
WoodheadM, BlasiF, EwigS, et al.Guidelines for the management of adult lower respiratory tract infections. Eur Respir J, 2005; 26:1138–1180.
6.
BourbeauJ, FordG, ZackonH, et al.Impact on patients' health status following early identification of a COPD exacerbation. Eur Respir J, 2007; 30:907–913.
7.
OliveiraAS, MunhaJ, BugalhoA, et al.Identification and assessment of COPD exacerbations. Pulmonology, 2017; 24:42–47.
8.
ShayaFT, ManevalMS, GbarayorCM, et al.Burden of COPD, asthma, and concomitant COPD and asthma among adults: Racial disparities in a medicaid population. Chest, 2009; 136:405–411.
9.
WilkinsonTM, DonaldsonGC, HurstJR, et al.Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2004; 169:1298–1303.
10.
SinDD, McAlisterFA, ManSFP, et al.Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA, 2003; 290:2301–2312.
11.
GeorgeJ, Ioannides-DemosLL, SantamariaNM, et al.Use of complementary and alternative medicines by patients with chronic obstructive pulmonary disease. Med J Australia, 2004; 181:248–251.
12.
RamA, BalachandarS, VijayananthP, et al.Medicinal plants useful for treating chronic obstructive pulmonary disease (COPD): Current status and future perspectives. Fitoterapia, 2011; 82:141–151.
13.
AnX, ZhangAL, MayBH, et al.Oral Chinese herbal medicine for improvement of quality of life in patients with stable chronic obstructive pulmonary disease: A systematic review. J Alternat Complement Med (New York, N.Y.), 2012; 18:731–743.
14.
LiFS, ZhangYL, LiZ, et al.Randomized, double-blind, placebo-controlled superiority trial of the Yiqigubiao pill for the treatment of patients with chronic obstructive pulmonary disease at a stable stage. Exp Ther Med, 2016; 12:2477–2488.
15.
ZhenG, JingJ, DanX, et al.A randomized controlled study of the Yi Qi Gu Biao Pill in the treatment of frequent exacerbator phenotype in chronic obstructive pulmonary disease (Lung and Spleen Qi Deficiency Syndrome). eCAM, 2017; 2017:9130804.
16.
LiJS, LiSY, XieY, et al.The effective evaluation on symptoms and quality of life of chronic obstructive pulmonary disease patients treated by comprehensive therapy based on traditional Chinese medicine patterns. Complement Ther Med, 2013; 21:595–602.
17.
ChangLC, HuangN, ChouYJ, et al.Utilization patterns of Chinese medicine and Western medicine under the National Health Insurance Program in Taiwan, a population-based study from 1997 to 2003. BMC Health Serv Res, 2008; 8:170.
18.
ChenFP, ChenTJ, KungYY, et al.Use frequency of traditional Chinese medicine in Taiwan. BMC Health Serv Res, 2007; 7:26.
19.
AfessaB, MoralesIJ, ScanlonPD, et al.Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med, 2002; 30:1610–1615.
20.
BarnesPJ, CelliBR. Systemic manifestations and comorbidities of COPD. Eur Respir J, 2009; 33:1165–1185.
21.
SorianoJB, VisickGT, MuellerovaH, et al.Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest, 2005; 128:2099–2107.
22.
KunisakiKM, DransfieldMT, AndersonJA, et al.Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med, 2018; 198:51–57.
23.
GläserS, KrügerS, MerkelM, et al.Chronic obstructive pulmonary disease and diabetes mellitus: A systematic review of the literature. Respiration, 2015; 89:253–264.
24.
PortegiesML, LahousseL, JoosGF, et al.Chronic obstructive pulmonary disease and the risk of stroke. The Rotterdam Study. Am J Respir Crit Care Med, 2016; 193:251–258.
25.
BarnesPJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol, 2016; 138:16–27.
26.
StockleyRA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med, 1999; 160(5 Pt 2):S49–S52.
ShinNR, KimC, SeoCS, et al.So-Cheong-Ryoung-Tang attenuates pulmonary inflammation induced by cigarette smoke in bronchial epithelial cells and experimental mice. Front Pharmacol, 2018; 9:1064.
30.
WangH, MaoB, ChenC. Xiaoqinglong decoction attenuates chronic obstructive pulmonary disease in rats via inhibition of autophagy. eCAM, 2018; 2018:6705871.
31.
ZhangY, GuoH, ChengBC, et al.Dingchuan tang essential oil inhibits the production of inflammatory mediators via suppressing the IRAK/NF-kappaB, IRAK/AP-1, and TBK1/IRF3 pathways in lipopolysaccharide-stimulated RAW264.7 cells. Drug Design Dev Ther, 2018; 12:2731–2748.
32.
JingL. Clinical observation of modified dingchuan decoction for acute exacerbation of chronic obstructive pulmonary disease. J N Chin Med, 2011; 43:22–24.
33.
MukaidaK, HattoriN, KondoK, et al.A pilot study of the multiherb Kampo medicine bakumondoto for cough in patients with chronic obstructive pulmonary disease. Phytomedicine, 2011; 18:625–629.
34.
AizawaH, ShigyoM, NakanoH, et al.Effect of the Chinese herbal medicine, Bakumondo-to, on airway hyperresponsiveness induced by ozone exposure in guinea-pigs. Respirology (Carlton, Vic.), 1999; 4:349–354.
WangD, WangS, ChenX, et al.Antitussive, expectorant and anti-inflammatory activities of four alkaloids isolated from Bulbus of Fritillaria wabuensis. J Ethnopharmacol, 2012; 139:189–193.
37.
ChoiJH, HwangYP, HanEH, et al.Inhibition of acrolein-stimulated MUC5AC expression by Platycodon grandiflorum root-derived saponin in A549 cells. Food Chem Toxicol, 2011; 49:2157–2166.
38.
MiyagoshiM, AmagayaS, OgiharaY. Antitussive effects of L-ephedrine, amygdalin, and makyokansekito (Chinese traditional medicine) using a cough model induced by sulfur dioxide gas in mice. Planta Medica, 1986; 52:275–278.
39.
WuZ, TanB, ZhangH, et al.Effects of sodium houttuyfonate on pulmonary inflammation in COPD model rats. Inflammation, 2017; 40:2109–2117.
40.
LiH, HungA, LiM, et al.Fritillariae thunbergii Bulbus: Traditional uses, phytochemistry, pharmacodynamics, pharmacokinetics and toxicity. Int J Mol Sci, 2019; 20:1667.
41.
ZhangL, WangY, YangD, et al.Platycodon grandiflorus—An ethnopharmacological, phytochemical and pharmacological review. J Ethnopharmacol, 2015; 164:147–161.
42.
ChaoualiN, GanaI, DorraA, et al.Potential toxic levels of cyanide in almonds (Prunus amygdalus), apricot kernels (Prunus armeniaca), and almond syrup. ISRN Toxicol, 2013; 2013:610648.
43.
KimMH, HongSU, KimHT, et al.A multicenter study on the efficacy and safety of So-Cheong-Ryong-Tang for perennial allergic rhinitis. Complement Ther Med, 2019; 45:50–56.
44.
HsuCH, LuCM, ChangTT. Efficacy and safety of modified Mai-Men-Dong-Tang for treatment of allergic asthma. Pediatr Allergy Immunol, 2005; 16:76–81.
45.
ChanCK, KuoML, ShenJJ, et al.Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: A randomized, double-blind clinical trial. Pediatr Allergy Immunol, 2006; 17:316–322.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
